NeuroPace, Inc.
NPCE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.45 | 0.24 | -0.03 | 0.21 |
| FCF Yield | -5.60% | -7.46% | -102.25% | -10.13% |
| EV / EBITDA | -23.28 | -14.05 | -2.73 | -9.77 |
| Quality | ||||
| ROIC | -26.64% | -29.20% | -44.23% | -20.18% |
| Gross Margin | 73.94% | 73.56% | 71.38% | 74.00% |
| Cash Conversion Ratio | 0.66 | 0.60 | 0.78 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.63% | 13.13% | 3.43% | 6.91% |
| Free Cash Flow Growth | 8.15% | 46.96% | -50.12% | -15.18% |
| Safety | ||||
| Net Debt / EBITDA | -3.61 | -2.38 | -1.73 | -1.08 |
| Interest Coverage | -2.46 | -3.19 | -5.42 | -3.20 |
| Efficiency | ||||
| Inventory Turnover | 1.56 | 1.54 | 1.34 | 1.50 |
| Cash Conversion Cycle | 241.49 | 256.11 | 271.96 | 257.49 |